Stocks/MPLT

MPLT

MapLight Therapeutics, Inc.
Healthcare·Biotechnology
$29.31
$23M market cap
Revenue
$0.0M
Free Cash Flow
$-98.4M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's diseas

2-Year Price History

$28.75+69.9%
$14$16$18$20$22$24$26$28$30volOct 25Dec 25Jan 26Feb 26Mar 26Apr 26

Quarterly Financials & Projections

Quarterly Waterfall ($ M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Act2026-Q10.0-64.3-64.5-60.7-51.2-51.2-0.0310.15.645.3-275.3%----
Act2025-Q40.0-83.2-83.4-79.6-46.8-47.2-0.4305.15.844.0-215.5%----

Valuation & Metrics

Market Stats

Price$29.31
Market Cap$23M
Enterprise Value$-281M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-425.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD

TTM Financial Snapshot

Revenue$0.0M
Net Income$-140.2M
Free Cash Flow$-98.4M

Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-245.4%
WC Change % Rev0.0%
Interest Coverage--

Forward Outlook & Risk

Short Interest

Short % of Float--
Short Shares1.7M
Days to Cover4.9
Change (vs Prior)+3.7%
Need at least 2 settlement dates for chart

Employees

Headcount109
Revenue / Employee$0
Gross Profit / Employee$-2,771

Cash Runway

37.8months
WATCH

Institutional Ownership

Headline & net flow

NEUTRAL
Net flow · still filing
No float data — flow unavailable.

Ownership composition

Active
1915.9%(+342.6% YoY)
71 filers
hedge / family / endowment
Retail funds
Fidelity, Schwab, 401(k)
Passive
293.2%(+84.3% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.2%(-0.0% YoY)
1 filers
Citadel, Susquehanna
Insiders
Form 4 — latest per insider
0%25%50%75%100%2025-122026-03
ActiveRetail fundsPassiveMarket makersRetail direct

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
Novo Holdings A/S$74.9M$17.57+$0+$74.9M-3.3%$1.23B
FCPM III SERVICES B.V.$65.6M$17.57+$0+$65.6M-3.1%$722M
T. Rowe Price Investment Management, Inc.$57.0M$17.57+$56K+$57.0M-1.3%$145.22B
GOLDMAN SACHS GROUP INC$40.6M$17.65+$1.2M+$40.6M-0.2%$760.93B
BlackRock, Inc.Passive$27.2M$18.07+$5.0M+$27.2M-0.2%$5.69T
Blue Owl Capital Holdings LP$20.5M$19.43+$13.8M+$20.5M-2.3%$372M
Nan Fung Group Holdings Ltd$19.7M$17.57+$0+$19.7M-4.2%$120M
5AM Venture Management, LLC$19.3M$17.57+$0+$19.3M+0.9%$360M
Sanofi$18.5M$17.57+$0+$18.5M+3.8%$336M
VANGUARD CAPITAL MANAGEMENT LLCPassive$14.6M$20.33+$14.6M+$14.6M$4.04T
Pivotal bioVenture Partners Investment Advisor LLC$12.4M$17.57+$0+$12.4M+1.7%$280M
Velan Capital Investment Management LP$10.0M$17.57−$598K+$10.0M-5.5%$160M
GEODE CAPITAL MANAGEMENT, LLCPassive$9.8M$18.10+$1.9M+$9.8M+2.3%$1.61T
Siren, L.L.C.$9.1M$17.57+$0+$9.1M+6.1%$3.61B
Vestal Point Capital, LP$8.5M$17.80+$712K+$8.5M-0.1%$3.58B
ADAR1 Capital Management, LLC$7.6M$20.33+$7.6M+$7.6M+8.3%$1.64B
BAKER BROS. ADVISORS LP$7.4M$17.57+$0+$7.4M-0.5%$16.13B
STATE STREET CORPPassive$6.9M$18.46+$2.2M+$6.9M-0.2%$2.89T
Freestone Grove Partners LP$6.4M$18.71+$2.6M+$6.4M+1.2%$13.77B
BNP Paribas Asset Management Holding S.A.$5.4M$18.81+$2.4M+$5.4M-1.1%$85.48B
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.14%
avg per quarter
Holders (ex-self)
-1.22%
excl. this stock
Buyers (this Q)
-0.20%
47 buyers · $0.11B in
Sellers (this Q)
+1.42%
13 sellers · $0.00B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
+1.9%
how holders react when this stock falls
On quiet Qs
-3.5%
−10% to +10% baseline
On rallies (+10%+)
+3.4%
how they react when this stock rises
Holders' portfolio flow this Q
-3.6%
outflows — trims may be forced
Sellers' portfolio flow this Q
-10.4%
Sellers shed AUM broadly — partly forced.

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

04.2M8.3M12.5M16.7M$18$18$19$20$202025-122026-03
hover the chart for per-quarter detailprice (right axis)
Novo Holdings A/S3.7MFCPM III SERVICES B.V.3.2MT. Rowe Price Investment Management, Inc.2.8MGOLDMAN SACHS GROUP INC2.0MBlue Owl Capital Holdings LP1.0MNan Fung Group Holdings Ltd971K5AM Venture Management, LLC950KSanofi912KPivotal bioVenture Partners Investment Advisor LLC611KVelan Capital Investment Management LP493K

Related Stocks

Investors who own this also own

Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.

TickerNameCo-holdersScore
EVMNEvommune, Inc.3173.78×
CLDXCelldex Therapeutics, Inc.3112.45×
PCVXVaxcyte, Inc.379.65×

Analyst Coverage

Analyst Coverage
Price Targets
Last Quarter (2 analysts)$44.005010.0%
Last Year (6 analysts)$35.332050.0%
Current Price$29.31

Corporate

Order Flow (FINRA, ~3w lag)

7.4%retail+0.4pp
25.6%dark-1.6pp
week of 2026-04-13
10%20%30%40%25-1025-1226-0126-0226-0326-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.